Industry News
Pharmaceutical Industry News
CG Life has hired Collette…
CG Life has hired Collette “Coco” Douaihy, bringing the former Dentsu International, Evoke and Digitas Health leader on board to head up its creative offering to biopharma companies.
Tarsus Pharmaceuticals has spent…
Tarsus Pharmaceuticals has spent the past three years marketing its way out of a largely unknown but stigmatized condition: Demodex blepharitis, an eyelid disease caused by mites.
How targeted protein degraders…
How targeted protein degraders could eliminate KRAS and redefine cancer care – insights from Astellas’ Head of Oncology Development
How Has Your Shopping Changed in the Era of Weight-Loss Drugs?
In the last few years, weight-loss drugs like Ozempic have altered how many Americans think about clothes and getting dressed.
Two months after UCB revealed the…
Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis, the Belgian drugmaker has unveiled the results. In the phase 3b study, 49% of
Roche has signed a voluntary…
Roche has signed a voluntary license agreement providing its popular influenza antiviral drug Xofluza for generic drugmakers to copy in 129 developing countries.
With questions already swirling…
With questions already swirling about the actual affordability impact of the government’s drug purchasing portal TrumpRx, the White House is updating the platform to address a key gap in the medicines it lists, albeit with
Takeda plans to appeal after a…
Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure that could be roughly tripled
TrumpRx Adds Generic Drugs, With Mark Cuban, GoodRx and Amazon
President Trump announced the addition of 600 medicines to his online drugstore as he appeals to Americans concerned about high drug prices and affordability.
A Novartis cross-border…
A Novartis cross-border partnership is turning into a standoff. The Swiss pharma has unilaterally terminated a plant leasing contract with Chinese CDMO Porton Pharma Solutions after a regulatory hiccup.
Following a string of defeats for…
Following a string of defeats for the industry in challenging the Inflation Reduction Act, Hail Mary efforts from a handful of companies to have their criticisms heard by the United States’ High Court have fallen
After an impressive phase 3…
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off, with an FDA approval Monday that also advances the British
Merck and Kelun-Biotech have…
Merck and Kelun-Biotech have already notched four approvals in China for their TROP2-directed ADC sacituzumab tirumotecan. Now, after meeting the primary endpoints in a phase 3 trial of certain patients with endometrial cancer, the companies
Already tracking $5 billion in…
Already tracking $5 billion in annual sales, Enhertu has secured two new FDA approvals for treating early breast cancer. But while arriving nearly two months early, the adjuvant label comes with a catch.
As Bristol Myers looks for…
As Bristol Myers looks for suitable sites for a large U.S. manufacturing plant, Houston has emerged as one contender.
BeOne Medicines has tapped former…
BeOne Medicines has tapped former professional soccer goalkeeper Tim Howard as the face of its first major corporate campaign, which plays on how the company is geared up to “save” lives.
Top Drug Regulator Is Fired From the F.D.A.
Dr. Tracy Beth Hoeg said she did not know who had fired her or why, but the dismissal came amid tumult at the agency in recent days.
The FDA approved the Tecentriq…
The FDA approved the Tecentriq label expansion alongside Natera's Signatera as a companion diagnostic.
With the ink barely dry on…
With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at the FDA.
The company doubled sales of its…
The company doubled sales of its Biogen-partnered Alzheimer's disease treatment during its 2025 fiscal year.